GROW
U.S. Global Investors, Inc.
There isn't enough reported data to score GROW yet.
IREN
IREN Limited
There isn't enough reported data to score IREN yet.
GROW Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| N/A | |
| N/A |
GROW's revenue is currently healthy, and its profitability is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like GROW.
IREN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| N/A | |
| N/A |
IREN's revenue and profitability are currently under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IREN.
GROW PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 4x | $0.52 | -79% |
| Fair | 13x | $1.68 | -33% |
| Current | 19x | $2.52 | — |
| Expensive | 35x | $4.53 | +80% |
Historical ranges are pointers, not guarantees.
GROW's PE is 19x, but its earnings don't support one, so it isn't a reliable read right now.
IREN PE Valuation
IREN has no meaningful PE right now: it lost money over the past year.
GROW Forward outlook
There aren't enough analyst estimates for GROW to show an outlook.
IREN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect IREN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
GROW Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.13 | +86% |
| Q2 2026 | $0.24 | +$0.27 |
| Q1 2026 | $0.25 | +$0.26 |
| Q4 2025 | $0.01 | -50% |
| Q3 2025 | $0.07 | -42% |
| Q2 2025 | -$0.03 | -133% |
| Q1 2025 | -$0.01 | -108% |
| Q4 2024 | $0.02 | -91% |
GROW has the edge over IREN on earnings quality, reporting a profit while its opponent remains loss making.
IREN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.96 | -347% |
| Q2 2026 | -$2.22 | -988% |
| Q1 2026 | $0.51 | +$1.10 |
| Q4 2025 | $1.18 | +$1.62 |
| Q3 2025 | $1.60 | +$1.99 |
| Q2 2025 | $0.25 | +$0.45 |
| Q1 2025 | -$0.59 | -$0.43 |
| Q4 2024 | -$0.44 | -$0.15 |
IREN has swung to a loss: it lost $3.96 per share over the past year, after a profit the year before.
GROW Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.7M | +18% |
| Q2 2026 | $2.7M | +39% |
| Q1 2026 | $2.8M | +31% |
| Q4 2025 | $2.5M | +13% |
| Q3 2025 | $2.3M | +4.4% |
| Q2 2025 | $2M | -20% |
| Q1 2025 | $2.1M | -19% |
| Q4 2024 | $2.2M | -21% |
GROW's revenue is recovering but still below its 2021 peak: $3M last quarter, up 18% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.1% | +25 points |
| Q2 2026 | -3.2% | +48 points |
| Q1 2026 | 3.2% | +46 points |
| Q4 2025 | -3.5% | +21 points |
| Q3 2025 | -23% | +3 points |
| Q2 2025 | -51% | -35 points |
| Q1 2025 | -42% | -24 points |
| Q4 2024 | -24% | -31 points |
GROW has the edge over IREN on profitability, with a higher operating margin.
IREN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $228M | -5.1% |
| Q2 2026 | $137.2M | -27% |
| Q1 2026 | $144.8M | 0% |
| Q4 2025 | $184.7M | +59% |
| Q3 2025 | $240.3M | +355% |
| Q2 2025 | $187.3M | +230% |
| Q1 2025 | $144.8M | +168% |
| Q4 2024 | $116.1M | +176% |
IREN has the edge over GROW on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -82% | -50 points |
| Q2 2026 | -452% | -461 points |
| Q1 2026 | -161% | -180 points |
| Q4 2025 | -63% | -79 points |
| Q3 2025 | -32% | +57 points |
| Q2 2025 | 9% | +49 points |
| Q1 2025 | 19% | +8 points |
| Q4 2024 | 15% | +21 points |
IREN's operating margin was −82% last quarter, down 50 points from the same quarter a year ago.
GROW Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $483K | +$515K |
| Q2 2026 | $203K | +$218K |
| Q1 2026 | $275K | +$699K |
| Q3 2025 | -$32K | -300% |
| Q2 2025 | -$15K | -115% |
| Q1 2025 | -$424K | -$299K |
| Q4 2024 | -$406K | -$380K |
| Q3 2024 | $16K | -98% |
GROW has the stronger cash trend. Its trailing FCF is down 72% versus its history, compared with IREN at down 479%.
IREN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$1.6B |
| Q2 2026 | $482.2M | +2895% |
| Q1 2026 | -$873.8M | -$523.1M |
| Q4 2025 | -$468M | -$334M |
| Q3 2025 | -$38M | +$349.4M |
| Q2 2025 | $16.1M | +$179M |
| Q1 2025 | -$350.7M | -$128.7M |
| Q4 2024 | -$134M | -$105.2M |
IREN's free cash flow was −$2.5B over the past year, against −$507M the year before. Free cash flow isn't a meaningful measure for financial services companies like IREN.
GROW Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.8% | -360K shares |
| 1 year | -5% | -648K shares |
| 3 years | -15% | -2.1M shares |
| 5 years | -18% | -2.7M shares |
| Available history | -19% | -2.8M shares |
GROW has the edge over IREN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $320,000 |
| Q2 2026 | $364,000 |
| Q1 2026 | $552,000 |
| Q4 2025 | $666,000 |
| Q3 2025 | $390,000 |
| Q2 2025 | $395,000 |
| Q1 2025 | $453,000 |
| Q4 2024 | $591,000 |
GROW spent $2M buying back its own shares over the past year, up 4% from the year before.
IREN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +82.4M shares |
| 1 year | +10% | +36.9M shares |
| 3 years | +511% | +333M shares |
| 5 years | +624% | +344M shares |
| Available history | +2346% | +382M shares |
IREN has 399M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
GROW Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2,691.6x | Net Cash |
| Q1 2024 | -61.7x | Net Cash |
| Q4 2023 | -16.3x | Net Cash |
| Q3 2023 | -11.2x | Net Cash |
| Q2 2023 | -6.7x | Net Cash |
| Q1 2023 | -4.0x | Net Cash |
| Q4 2022 | -2.9x | Net Cash |
| Q3 2022 | -2.3x | Net Cash |
GROW has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like GROW.
IREN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 157.6x | High |
| Q4 2025 | 22.2x | High |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 2.0x | Moderate |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | -4.6x | Net Cash |
| Q3 2024 | -16.7x | Net Cash |
| Q2 2024 | -15.9x | Net Cash |
IREN's net debt is more than 20 years of its operating earnings (EBITDA), up from 3.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like IREN.
GROW Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.3 | Neutral |
| Stochastic | 6.4 | Oversold |
GROW's weekly RSI is 38 (neutral) and its Stochastic is 6 (oversold).
IREN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.3 | Neutral |
| Stochastic | 8.2 | Oversold |
IREN's weekly RSI is 33 (neutral) and its Stochastic is 8 (oversold).
GROW PE vs Financial Services Sector
| Metric | GROW | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 13x | 49% above |
| PE % | 60 | 63 | 3 pts below |
GROW is trading at 19x earnings, a 49% premium to the Financial Services sector's median of 13x, though its earnings don't support one.
IREN PE vs Financial Services Sector
| Metric | IREN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IREN has no meaningful PE right now: it lost money over the past year.
GROW Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.72 | 7.4% below |
| 20 week MA | $2.92 | 14% below |
| 50 week MA | $2.84 | 11% below |
| 100 week MA | $2.62 | 3.8% below |
| 200 week MA | $2.68 | 6% below |
GROW is in a downtrend: it's below all five of its weekly moving averages, and 6% below its 200-week average.
IREN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.8 | 35% below |
| 20 week MA | $36.2 | 46% below |
| 50 week MA | $42.8 | 54% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $19.1 | 2.1% above |
IREN has the edge over GROW on trend strength, trading above more of its moving averages.
GROW Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.33 | $4.62 | +247% |
| 2021 | $4.62 | $4.55 | -1.5% |
| 2022 | $4.55 | $2.65 | -42% |
| 2023 | $2.65 | $2.82 | +6.4% |
| 2024 | $2.82 | $2.45 | -13% |
| 2025 | $2.45 | $2.47 | +0.8% |
| 2026 YTD | $2.47 | $2.52 | +2% |
GROW has the edge over IREN on returns for 2026, with the stronger performance.
IREN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.8 | $17.2 | -31% |
| 2022 | $17.2 | $1.19 | -93% |
| 2023 | $1.19 | $7.15 | +501% |
| 2024 | $7.15 | $10.7 | +50% |
| 2025 | $10.7 | $40.3 | +276% |
| 2026 YTD | $40.3 | $19.5 | -52% |
IREN's yearly returns have swung widely, from +501% in 2023 to −93% in 2022. It's down 52% so far in 2026.